Ulla Hald Buhl

Biography

Hald Buhl, born 1964, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and since March 2015 a member of the Board of Directors of the wholly owned subsidiary Oncology Venture ApS. Hald Buhl has a broad background in clinical trials, organisation management and communications. Hald Buhl has previously been in charge of TopoTarget A/S’s investor relations department and is currently active in this area in both Swedish WNT Research AB (listed on AktieTorget) as well as Danish Medical Prognosis Institute A/S (listed on NASDAQ First North in Copenhagen). During 1999-2001, Hald Buhl worked as a Team Leader in oncology at AstraZeneca A/S and during 2001-2005 Hald Buhl was the head of the regulatory department of TopoTarget A/S. Owns 20%* of Buhl Krone Holding ApS ** which owns 1,000,000 shares of the Company. Holds 5,000 warrants in the Company.The remaining 80% is owned by Peter Buhl Jensen, who is Ulla Hald Buhl’s husband and CEO of Oncology Venture.The same corporate registration number as Buhl Oncology ApS.

Research Interest

Hald Buhl has a broad background in clinical trials, organisation management and communications. Hald Buhl has previously been in charge of TopoTarget A/S’s investor relations department and is currently active in this area in both Swedish WNT Research AB (listed on AktieTorget) as well as Danish Medical Prognosis Institute A/S (listed on NASDAQ First North in Copenhagen).